US FDA grants fast track designation to NKGen Biotech’s natural killer cell therapy, troculeucel to treat moderate Alzheimer’s disease: Santa Ana, California Saturday, Februar ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

A recent drug discovery could eventually help the visually impaired and those suffering from multiple sclerosis, traumatic stroke, and Alzheimer’s disease regain some of their vision and mental ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

The Crimson spoke to a range of commercial realtors, startup founders, and a commercial lab space owner to understand how the immense draw of Kendall Square has forced the myriad startup companies ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Billions of years ago, the molecular building blocks of life emerged from a complex web of chemical and geological processes.

Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

“If small biotech companies like ours are forced to scale back or shut down, it will not just be a loss for scientific ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...